0541 GMT - CSPC Pharmaceutical Group may benefit from higher success odds of its 'SYS6010' antibody-drug conjugate, China Galaxy International's Lily Wang says in a research report. SYS6010 has demonstrated tolerable safety and promising efficacy in both Epidermal Growth Factor Receptor-mutant and EGFR wild-type non-small cell lung cancer, the analyst notes. Also, management highlighted its business development performance in 2025 could exceed its previous guidance of 2-3 more deals, including at least three out-licensing deals worth over US$5 billion each, the analyst adds. The brokerage raises the stock's target price to HK$10.04 from HK$7.43 with an unchanged add rating. Shares are 6.2% lower at HK$7.60. (ronnie.harui@wsj.com)
(END) Dow Jones Newswires
June 02, 2025 01:41 ET (05:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。